Explain this page
Arphra AIPlain-English read on Becton, Dickinson and Company’s valuationAI Issuer Brief
Arphra AILoading cached brief…
Price change · trailing returns
Live| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.22% | -1.54% | -2.67% | -17.65% | -3.63% | -4.75% | +9.12% | -25.49% | -20.54% | +13.43% | +528.59% |
Aftermarket
LiveLast trade
$147.00
476 sh
Bid
$145.45
30 sh
Ask
$147.00
200 sh
Spread
$1.550
Sector & industry today
LiveSectors
- Technology+0.67%
- Basic Materials+0.15%
- Communication Services+0.13%
- Real Estate-0.13%
- Industrials-0.48%
- Energy-0.58%
- Healthcare-0.65%
- Financial Services-0.80%
- Consumer Defensive-0.85%
- Consumer Cyclical-0.85%
- Utilities-1.15%
Top industries (issuer's industry highlighted)
- Medical - Instruments & Supplies+1.72%
- Computer Hardware+8.35%
- Software - Infrastructure+7.61%
- Coal+5.76%
- Consulting Services+5.28%
- Medical - Healthcare Information Services+5.23%
- Medical - Diagnostics & Research+4.96%
- REIT - Healthcare Facilities-3.49%
- Broadcasting-3.48%
- Software - Application+3.44%
- Advertising Agencies+3.24%
- Biotechnology+3.22%
Fair value
Football field →Weighted blend
$348.65
+139.90% vs spot
Recommendation
Strong Buy
18 of 19 methods
Method spread
7bull7bear
±5% threshold
Analyst PT consensus: $172.85 (+18.94%)
Total assets
$55.33B
Total debt
$19.18B
Cash & equiv
$851M
Operating CF
$3.43B
Free cash flow
$2.67B
Buybacks
-$1B
Analyst view
DB · price_targets + analyst_gradesConsensus target
$172.85
+18.94% upside
Low
$159.00
Median
$168.01
High
$202.00
Recent actions
0 ↑0 ↓8 hold
- Apr 01, 2026
- Mar 01, 2026
- Feb 01, 2026
- Jan 01, 2026
- Dec 01, 2025
News
DB · news_items- Becton, Dickinson and Company (BDX) Presents at Bank of America Global Healthcare Conference 2026 Transcriptseekingalpha.com·May 12, 2026
- BD Appoints Vitor Roque Chief Financial Officerprnewswire.com·May 07, 2026
- BD Reports Second Quarter Fiscal 2026 Financial Resultsprnewswire.com·May 07, 2026
- Can Sustained Product Momentum Drive BDX Stock Before Q2 Earnings?zacks.com·May 04, 2026
Recent quarters
All financials →| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q1 Dec 2025 | $5.25B | $382M | $1.34 |
| Q4 Sep 2025 | $5.89B | $493M | $1.72 |
| Q3 Jun 2025 | $5.51B | $574M | $2.00 |
| Q2 Mar 2025 | $5.27B | $308M | $1.07 |
| Q1 Dec 2024 | $5.17B | $303M | $1.04 |
| Q4 Sep 2024 | $5.44B | $400M | $1.45 |
Recent insiders
All →| Insider | Action | Shares | Value | Date |
|---|---|---|---|---|
Feld Michael officer: EVP, Chief Revenue Officer | Sell | 74 | $11.24K | Apr 27, 2026 |
Feld Michael officer: EVP, Chief Revenue Officer | Sell | 75 | $11.76K | Mar 26, 2026 |
Feld Michael officer: EVP, Chief Revenue Officer | Sell | 75 | $13.64K | Feb 26, 2026 |
SCOTT BERTRAM L director | Sell | 953 | $174.03K | Feb 18, 2026 |
Feld Michael officer: EVP, CRO & Pres. Life Sciences | Sell | 75 | $15.2K | Jan 26, 2026 |
Garrison Michael David officer: EVP & Pres Med.Essntl&BioPharm | Sell | 1,010 | $208.61K | Jan 15, 2026 |
Income statement · annual
5y| Period | Revenue | Op income | Net income | EPS | Net margin |
|---|---|---|---|---|---|
| FY 2025 | $21.84B | $2.58B | $1.68B | $5.83 | +7.68% |
| FY 2024 | $20.18B | $2.4B | $1.71B | $5.86 | +8.45% |
| FY 2023 | $19.37B | $2.11B | $1.48B | $4.94 | +7.66% |
| FY 2022 | $18.87B | $2.28B | $1.78B | $5.88 | +9.43% |
| FY 2021 | $19.13B | $2.25B | $2.09B | $6.85 | +10.94% |